tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VALN Stock Latest News

Valneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data
Company AnnouncementsValneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data
4d ago
6K
VALN
Valneva Regains Full Rights to Chikungunya Vaccine as Serum Institute License Ends
PremiumCompany Announcements
Valneva Regains Full Rights to Chikungunya Vaccine as Serum Institute License Ends
13d ago
6K
VALN
Valneva, Serum Institute of India discontinue chikungunya vaccine pact
PremiumThe Fly
Valneva, Serum Institute of India discontinue chikungunya vaccine pact
13d ago
VALN
Valneva Reports Positive Phase 2 Results for Chikungunya Vaccine in Children
PremiumCompany Announcements
Valneva Reports Positive Phase 2 Results for Chikungunya Vaccine in Children
1M ago
6K
VALN
Valneva reports ‘positive’ final Phase 2 results for chikungunya vaccine
PremiumThe Fly
Valneva reports ‘positive’ final Phase 2 results for chikungunya vaccine
1M ago
VALN
Valneva Announces Strategic Consolidation of French Operations
PremiumCompany AnnouncementsValneva Announces Strategic Consolidation of French Operations
2M ago
6K
VALN
Valneva Reports Nine-Month 2025 Financial Results and Updates on Vaccine Developments
Premium
Company Announcements
Valneva Reports Nine-Month 2025 Financial Results and Updates on Vaccine Developments
2M ago
6K
VALN
Valneva SE Reports 2025 Nine-Month Financial Results
Premium
Company Announcements
Valneva SE Reports 2025 Nine-Month Financial Results
2M ago
VALN
Valneva Se’s Earnings Call: Mixed Results and Future Prospects
PremiumCompany Announcements
Valneva Se’s Earnings Call: Mixed Results and Future Prospects
2M ago
VALN
Valneva Reports Increased Revenues and Strategic Advances in Vaccine Development
PremiumCompany Announcements
Valneva Reports Increased Revenues and Strategic Advances in Vaccine Development
2M ago
6K
VALN
Valneva’s Promising Future: Buy Rating Backed by Strong Prospects for Lyme Disease Vaccine and Robust Financial Health
PremiumRatings
Valneva’s Promising Future: Buy Rating Backed by Strong Prospects for Lyme Disease Vaccine and Robust Financial Health
2M ago
VALN
Is VALN a Buy, Before Earnings?
PremiumPre-Earnings
Is VALN a Buy, Before Earnings?
2M ago
VALN
Valneva Reports Positive Phase 1 Results for Zika Vaccine Candidate
PremiumCompany AnnouncementsValneva Reports Positive Phase 1 Results for Zika Vaccine Candidate
2M ago
6K
VALN
Valneva Secures $500 Million Financing to Bolster Vaccine Pipeline
Premium
Company Announcements
Valneva Secures $500 Million Financing to Bolster Vaccine Pipeline
3M ago
6K
VALN
Valneva Reports Long-lasting Antibody Persistence for Chikungunya Vaccine
Premium
Company Announcements
Valneva Reports Long-lasting Antibody Persistence for Chikungunya Vaccine
3M ago
6K
VALN
Valneva price target lowered to $13 from $14 at Guggenheim
PremiumThe Fly
Valneva price target lowered to $13 from $14 at Guggenheim
4M ago
VALN
Valneva Reports Positive Phase 2 Results for Lyme Disease Vaccine
PremiumCompany Announcements
Valneva Reports Positive Phase 2 Results for Lyme Disease Vaccine
4M ago
6K
VALN
Valneva’s Stock: A Buy Rating Amid Overreaction and Promising Vaccine Prospects
PremiumRatings
Valneva’s Stock: A Buy Rating Amid Overreaction and Promising Vaccine Prospects
5M ago
VALN
Valneva selloff on FDA suspension overdone, says H.C. Wainwright
PremiumThe Fly
Valneva selloff on FDA suspension overdone, says H.C. Wainwright
5M ago
VALN
Valneva price target lowered to $14 from $18 at Jefferies
PremiumThe FlyValneva price target lowered to $14 from $18 at Jefferies
5M ago
VALN
Valneva announces U.S. FDA’s decision to suspend license of IXCHIQ
Premium
The Fly
Valneva announces U.S. FDA’s decision to suspend license of IXCHIQ
5M ago
VALN
Valneva Faces FDA Suspension of Chikungunya Vaccine License
Premium
Company Announcements
Valneva Faces FDA Suspension of Chikungunya Vaccine License
5M ago
6K
VALN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >